Genentech

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. F. Hoffmann-La Roche AG瑞士4
2. AbbVie (United States)美国4
3. Eli Lilly (United States)美国3
4. Bristol-Myers Squibb (United States)美国3
5. Bayer (Germany)德国2
6. Georgetown University美国2
7. Amgen (United States)美国2
8. United States Food and Drug Administration美国2

按月发文

逐年被引

最新文献

1. 1
   The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug‐Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI InitiativeDrug Safety20253
2. 2
   Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?Drug Safety20251
3. 3
   Clinical Performance Measures for Emergency Department Care for Adults With Intracranial HemorrhageAnnals of Emergency Medicine20231
4. 4
   Emerging reaction technologies in pharmaceutical development: Challenges and opportunities in electrochemistry, photochemistry, and biocatalysisProcess Safety and Environmental Protection202342
5. 5
   Industry Perspective on Artificial Intelligence/Machine Learning in PharmacovigilanceDrug Safety202239
6. 6
   Development of an impurity and hydrate form controlling continuous crystallization to telescope a two-step batch recrystallization in the GDC-4379 drug substance processProcess Safety and Environmental Protection20223
7. 7
   Development and evaluation of a proxy for baseline ECOG PS in advanced non‐small cell lung cancer, bladder cancer, and melanoma: An electronic health record studyPharmacoepidemiology and Drug Safety202115
8. 8
   Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisDrug Safety202041
9. 9
   Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?Drug Safety201912
10. 10
    Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine LearningDrug Safety201944

高被引文献

1. 1
   Regional disparities in the quality of stroke careAmerican Journal of Emergency Medicine201774
2. 2
   Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsDrug Safety201758
3. 3
   An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records databasePharmacoepidemiology and Drug Safety201954
4. 4
   Facilitating Partnerships With Community- and Faith-Based Organizations for Disaster Preparedness and Response: Results of a National Survey of Public Health DepartmentsDisaster Medicine and Public Health Preparedness201750
5. 5
   Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine LearningDrug Safety201944
6. 6
   Emerging reaction technologies in pharmaceutical development: Challenges and opportunities in electrochemistry, photochemistry, and biocatalysisProcess Safety and Environmental Protection202342
7. 7
   Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisDrug Safety202041
8. 8
   Industry Perspective on Artificial Intelligence/Machine Learning in PharmacovigilanceDrug Safety202239
9. 9
   Making a case for the right ‘-ase’ in acute ischemic stroke: alteplase, tenecteplase, and reteplaseExpert Opinion on Drug Safety201922
10. 10
    Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health systemPharmacoepidemiology and Drug Safety201516

主要发表期刊

研究主题